共 157 条
[1]
Proudman SM(2007)Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use Semin Arthritis Rheum 37 99-111
[2]
Keen HI(2003) metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes Drug Metab Dispos 31 1240-1250
[3]
Stamp LK(2009)Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on A771726 pharmacokinetics in leflunomide treated patients with rheumatoid arthritis Drug Metab Dispos 37 2061-2068
[4]
Lee AT(2009)Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance Ann Rheum Dis 68 1201-1207
[5]
Goldblatt F(2002)C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance Mol Cancer Ther 1 611-616
[6]
Ayres OC(2008)Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients Eur J Clin Pharmacol 64 871-876
[7]
Rischmueller M(2009)Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis Ann Rheum Dis 68 1367-1368
[8]
James MJ(2000)Leflunomide: mode of action in the treatment of rheumatoid arthritis Ann Rheum Dis 59 841-849
[9]
Hill CL(1988)The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 315-324
[10]
Caughey GE(2010)Effects of CYP2C19 genotype on outcomes of clopidogrel treatment N Engl J Med 363 1704-1714